slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
220,621-220,650 of 319,975
70
The slide highlights the technical methodology behind the 565 candidate development, specifically focusing on allosteric site constraints and permeability.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
71
The slide demonstrates efficacy and synergy in vivo for a drug candidate ('565) in DLBCL models.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
72
The slide uses two dose-response curves to demonstrate selectivity.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
73
The table uses a heatmap-style color coding (red/green) to indicate risk levels for UGT1A1 inhibition parameters.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
74
The slide uses a two-column layout to contrast PK data with Toxicology/Safety data.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
75
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
76
This is a standard closing/contact slide.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
01
Exscientia | Results Presentation Deck | 24 slidesExscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Setup1 hit
02
Exscientia | Results Presentation Deck | 24 slidesExscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Setup1 hit
03
Exscientia | Results Presentation Deck | 24 slidesExscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Setup1 hit
04
Exscientia | Results Presentation Deck | 24 slidesExscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
05
The chart uses a horizontal bar format to represent development stages.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
06
Exscientia | Results Presentation Deck | 24 slidesExscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
07
Uses MIDD (Model-informed drug development) as a strategic framework for clinical progression.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
08
The slide uses a human anatomy diagram to map specific patient counts to disease locations.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
09
Exscientia | Results Presentation Deck | 24 slidesExscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
10
The slide uses a process flow to show the mechanism of action for a drug candidate.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
11
The slide contrasts irreversible inhibition (depletion) with reversible inhibition (recovery).Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
12
The slide includes two charts: a line chart showing tumour volume over time and a dot plot showing plasma pro-GRP concentration reduction.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
13
The slide uses box plots for aggregate data and line charts for individual patient sample responses, categorized by differentiation level.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Evidence1 hit
14
The slide uses a heatmap to visualize synergy (green) vs no synergy (light green) across different drug combinations.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Evidence1 hit
15
Includes a heatmap showing synergy scores and two dose-response line charts demonstrating enhanced inhibition in combination treatments.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Evidence1 hit
16
Exscientia | Results Presentation Deck | 24 slidesExscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations 1 hit
17
Data shows significant synergistic effects in both models, with OCI-Ly10 showing regression and TMD8 showing synergy despite ibrutinib monotherapy inactivity.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations 1 hit
18
The slide shows dose-response curves for 11 patient samples. The left chart shows significant inhibition of CLL cells (IC50 0.4 µM), while the right chart shows minimal impact on T-cell viability.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations 1 hit
19
The table uses a heatmap-style color coding (red for high risk, green for low risk) to visualize safety metrics.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations 1 hit
20
Exscientia | Results Presentation Deck | 24 slidesExscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Key Messages1 hit
21
Uses a concentric circle diagram to represent the layers of value (Pipeline, Financial, Strategic).Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Key Messages1 hit
22
Includes footnote regarding fixed term bank deposits and currency basis.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Key Messages1 hit
23
Exscientia | Results Presentation Deck | 24 slidesExscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations Beat · Key Messages1 hit